RU2017101333A - Новые аналоги глюкагона - Google Patents
Новые аналоги глюкагона Download PDFInfo
- Publication number
- RU2017101333A RU2017101333A RU2017101333A RU2017101333A RU2017101333A RU 2017101333 A RU2017101333 A RU 2017101333A RU 2017101333 A RU2017101333 A RU 2017101333A RU 2017101333 A RU2017101333 A RU 2017101333A RU 2017101333 A RU2017101333 A RU 2017101333A
- Authority
- RU
- Russia
- Prior art keywords
- chem
- glucagon peptide
- peptide according
- compound
- paragraphs
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
- 108060003199 Glucagon Proteins 0.000 claims 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- -1 GLP-1 compound Chemical class 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 208000013016 Hypoglycemia Diseases 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 230000002218 hypoglycaemic effect Effects 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 4
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 102100040918 Pro-glucagon Human genes 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 108010011459 Exenatide Proteins 0.000 claims 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 2
- 229960001519 exenatide Drugs 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000003893 regulation of appetite Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11182476.9 | 2011-09-23 | ||
| EP11182476 | 2011-09-23 | ||
| US201161539148P | 2011-09-26 | 2011-09-26 | |
| US61/539,148 | 2011-09-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014114434A Division RU2610175C2 (ru) | 2011-09-23 | 2012-09-21 | Новые аналоги глюкагона |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2017101333A true RU2017101333A (ru) | 2018-12-19 |
Family
ID=47911932
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017101333A RU2017101333A (ru) | 2011-09-23 | 2012-09-21 | Новые аналоги глюкагона |
| RU2014114434A RU2610175C2 (ru) | 2011-09-23 | 2012-09-21 | Новые аналоги глюкагона |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014114434A RU2610175C2 (ru) | 2011-09-23 | 2012-09-21 | Новые аналоги глюкагона |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US8541368B2 (OSRAM) |
| EP (1) | EP2758426B1 (OSRAM) |
| JP (2) | JP6352806B2 (OSRAM) |
| KR (1) | KR20140070612A (OSRAM) |
| CN (1) | CN104093735B (OSRAM) |
| AR (1) | AR088161A1 (OSRAM) |
| AU (1) | AU2012311484B2 (OSRAM) |
| BR (1) | BR112014006684A2 (OSRAM) |
| CA (1) | CA2849673A1 (OSRAM) |
| IL (1) | IL231199A0 (OSRAM) |
| IN (1) | IN2014CN02448A (OSRAM) |
| MX (1) | MX354705B (OSRAM) |
| MY (1) | MY167234A (OSRAM) |
| RU (2) | RU2017101333A (OSRAM) |
| TW (1) | TWI596110B (OSRAM) |
| WO (1) | WO2013041678A1 (OSRAM) |
| ZA (1) | ZA201401603B (OSRAM) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289560B1 (en) * | 2004-07-08 | 2015-04-22 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| JP6054742B2 (ja) | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
| CA2849673A1 (en) | 2011-09-23 | 2013-03-28 | Novo Nordisk A/S | Novel glucagon analogues |
| JP6228187B2 (ja) | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| MX356957B (es) | 2012-07-23 | 2018-06-20 | Zealand Pharma As | Analogos del glucagon. |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| MX362190B (es) | 2012-12-21 | 2019-01-08 | Sanofi Sa | Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon. |
| PL2986313T3 (pl) * | 2013-04-18 | 2019-12-31 | Novo Nordisk A/S | Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych |
| HRP20191258T1 (hr) * | 2013-04-18 | 2019-10-18 | Novo Nordisk A/S | Stabilni, suagonisti receptora glp-1 i glukagonskog receptora s produljenim djelovanjem, namijenjeni upotrebi u medicini |
| MX2015016564A (es) | 2013-06-20 | 2016-04-15 | Novo Nordisk As | Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos. |
| CA2926314C (en) | 2013-10-17 | 2023-08-29 | Zealand Pharma A/S | Acylated glucagon analogues |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| CN105829339B (zh) | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
| AU2014345569B2 (en) | 2013-11-06 | 2020-08-13 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| KR20160114082A (ko) * | 2014-02-18 | 2016-10-04 | 노보 노르디스크 에이/에스 | 안정한 글루카곤 유사체 및 저혈당증의 치료를 위한 용도 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー／エス | 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| CN106519015B (zh) * | 2014-09-23 | 2020-04-17 | 深圳市图微安创科技开发有限公司 | 胃泌酸调节素类似物 |
| EP3204408B1 (en) | 2014-10-10 | 2020-05-06 | Novo Nordisk A/S | Stable glp-1 based glp-1/glucagon receptor co-agonists |
| EP3212218B1 (en) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Gip agonist compounds and methods |
| CN106999602B (zh) | 2014-11-27 | 2022-02-01 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| US10392428B2 (en) | 2014-12-17 | 2019-08-27 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
| JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| CA2980978A1 (en) | 2015-04-16 | 2016-10-20 | Zealand Pharma A/S | Acylated glucagon analogue |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| WO2017015538A1 (en) | 2015-07-22 | 2017-01-26 | Purdue Research Foundation | Modified glucagon molecules |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| AU2017207862B2 (en) * | 2016-01-13 | 2020-12-17 | Novo Nordisk A/S | EGF(A) analogues with fatty acid substituents |
| US11659854B2 (en) | 2017-07-13 | 2023-05-30 | Fuji Oil Holdings Inc. | Method for imparting body taste to food |
| WO2019016306A1 (en) | 2017-07-19 | 2019-01-24 | Novo Nordisk A/S | BIFUNCTIONAL COMPOUNDS |
| US11357861B2 (en) | 2017-09-29 | 2022-06-14 | Hanmi Pharm. Co., Ltd | Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor |
| JOP20190150A1 (ar) | 2018-06-21 | 2019-12-21 | Merck Sharp & Dohme | مركبات مناهضة لـ pcsk9 |
| US20220125885A1 (en) * | 2019-02-05 | 2022-04-28 | Eli Lilly And Company | Glucagon analog agonists and methods of using the same |
| EP4076492A4 (en) * | 2019-12-20 | 2024-01-17 | Merck Sharp & Dohme LLC | PCSK9 ANTAGONIST COMPOUNDS |
| TWI850611B (zh) * | 2020-12-18 | 2024-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及澱粉素受體之共促效劑 |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| WO2023044290A1 (en) | 2021-09-15 | 2023-03-23 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| CN113759048B (zh) * | 2021-10-14 | 2022-06-21 | 成都普康唯新生物科技有限公司 | 一种十八烷二酸单叔丁酯检验方法 |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| ZA90533B (en) | 1989-02-01 | 1990-10-31 | Shionogi & Co | A method for the production of glucagon |
| US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5480867A (en) * | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| CN1202105A (zh) | 1995-09-08 | 1998-12-16 | 诺沃挪第克公司 | 2－烷基吡咯烷化合物 |
| WO1997026265A1 (en) | 1996-01-17 | 1997-07-24 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| JP2000514041A (ja) | 1996-07-26 | 2000-10-24 | ドクター・レディーズ・リサーチ・ファウンデーション | 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物 |
| JP3149958B2 (ja) | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ―１誘導体 |
| ATE246190T1 (de) | 1996-12-31 | 2003-08-15 | Reddys Lab Ltd Dr | Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten |
| DE69727837T2 (de) | 1997-05-02 | 2004-12-30 | Dr. Reddy's Research Foundation, Hyderabad | Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel |
| AU749271B2 (en) | 1997-07-01 | 2002-06-20 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| RU2215004C2 (ru) | 1997-07-16 | 2003-10-27 | Ново Нордиск А/С | Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата |
| WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
| US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
| DE69803750T2 (de) | 1997-12-02 | 2002-09-12 | Dr. Reddy's Research Foundation, Andhra Pradesh | Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften |
| EP1123269A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| EP1123268A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2000023445A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2000023415A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| JP2002527507A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物類、それらの調製及び使用 |
| WO2000023451A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| EP1140945B1 (en) | 1998-12-18 | 2003-06-04 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| WO2000041121A1 (en) | 1999-01-07 | 2000-07-13 | Ccrewards.Com | Method and arrangement for issuance and management of digital coupons and sales offers |
| JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドｇｌｐ−１アゴニスト |
| EP1147092A1 (en) | 1999-01-18 | 2001-10-24 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| WO2000063193A1 (en) | 1999-04-16 | 2000-10-26 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
| AU3956900A (en) | 1999-04-16 | 2000-11-02 | Boehringer Ingelheim International Gmbh | Substituted imidazoles, their preparation and use |
| BR0010683A (pt) | 1999-04-16 | 2003-07-01 | Reddy Research Foundation | Formas polimórficas de um agente antidiabético: processo para seu preparo e composições farmacêuticas contendo o mesmo |
| WO2000063191A1 (en) | 1999-04-16 | 2000-10-26 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
| JP2002542218A (ja) | 1999-04-20 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 新規な化合物、それらの製造および使用 |
| AU3957900A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2000063209A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2000064884A1 (en) | 1999-04-26 | 2000-11-02 | Novo Nordisk A/S | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
| DK1180121T3 (da) | 1999-05-17 | 2004-03-01 | Conjuchem Inc | Langtidsvirkende insulinotrope peptider |
| EP1105409B1 (en) | 1999-05-17 | 2006-03-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| AU2001264791B2 (en) * | 2000-06-16 | 2006-11-23 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
| ATE297907T1 (de) | 2000-07-20 | 2005-07-15 | Hoffmann La Roche | Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase- aktivatoren |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| ES2411007T3 (es) | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| ES2291613T3 (es) | 2002-01-16 | 2008-03-01 | Biocompatibles Uk Limited | Conjugados de polimeros. |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| US7314859B2 (en) | 2002-12-27 | 2008-01-01 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| EP1503283A1 (en) | 2003-08-01 | 2005-02-02 | Hewlett-Packard Development Company, L.P. | Data processing system and method |
| EP2107069B1 (en) * | 2003-08-05 | 2013-01-16 | Novo Nordisk A/S | Novel insulin derivatives |
| WO2005016974A1 (en) | 2003-08-12 | 2005-02-24 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
| KR101241862B1 (ko) * | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| CN100444898C (zh) | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| RU2401276C2 (ru) | 2003-09-19 | 2010-10-10 | Ново Нордиск А/С | Производные глюкагон-подобного пептида-1 (glp-1) |
| KR101483917B1 (ko) | 2004-11-12 | 2015-01-16 | 바이엘 헬스케어 엘엘씨 | Ｆｖｉｉｉ의 부위 지향 변형 |
| US8217154B2 (en) | 2005-02-23 | 2012-07-10 | Lipoxen Technologies Limited | Activated sialic acid derivatives for protein derivatisation and conjugation |
| WO2006097536A2 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| US20080227691A1 (en) | 2005-04-01 | 2008-09-18 | Novo Nordisk Health Care Ag | Blood Coagulation FVIII Analogues |
| SI1891105T1 (sl) | 2005-06-13 | 2012-07-31 | Imp Innovations Ltd | Analogi oksintomodulina in njihovi učinki na prehranjevalno vedenje |
| AU2006259080A1 (en) | 2005-06-15 | 2006-12-21 | Novo Nordisk Health Care Ag | Transglutaminase mediated conjugation of growth hormone |
| BRPI0613984A2 (pt) | 2005-07-18 | 2011-03-01 | Novo Nordisk As | peptìdios para uso no tratamento da obesidade, seu uso e composição farmacêutica compreendendo os mesmos |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| EP2570133B1 (en) | 2005-11-07 | 2016-03-23 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| WO2007087711A1 (en) | 2006-01-31 | 2007-08-09 | National Research Council Of Canada | Production of polysialic acid containing glyconjugates using a self-priming polysialyltransferase |
| WO2007100535A2 (en) | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| MX2008012600A (es) | 2006-03-31 | 2008-12-12 | Baxter Int | Factor viii pegilado. |
| CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| BRPI0720282B8 (pt) | 2006-12-15 | 2021-05-25 | Baxalta GmbH | construção proteica, composição farmacêutica, e, kit |
| WO2008086086A2 (en) | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| KR20090119876A (ko) | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/ｇｌｐ-1 수용체 공동-항진물질 |
| CN101778937A (zh) | 2007-06-04 | 2010-07-14 | 诺和诺德公司 | 使用n-乙酰葡糖胺转移酶的o-联糖基化 |
| EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
| CN101730739B (zh) | 2007-06-15 | 2013-07-31 | 加拿大国家研究院 | 经工程改造的酶活性改善的聚唾液酸转移酶及其用途 |
| EP2190460B1 (en) * | 2007-09-05 | 2014-12-17 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| WO2009033780A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of growth hormone-releasing factor and/or k237 as a therapeutic agents |
| JP2011503101A (ja) | 2007-11-09 | 2011-01-27 | バクスター・インターナショナル・インコーポレイテッド | 修飾された組換え第ｖｉｉｉ因子およびフォンウィルブランド因子ならびにその使用方法 |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| CN102037004A (zh) | 2008-01-08 | 2011-04-27 | 生物种属学股份公司 | 使用寡糖基转移酶的多肽的糖缀合 |
| US20110065633A1 (en) | 2008-01-30 | 2011-03-17 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| RU2573587C2 (ru) | 2008-02-27 | 2016-01-20 | Ново Нордиск А/С | Конъюгированные молекулы фактора viii |
| AR072159A1 (es) | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad |
| JP5775450B2 (ja) * | 2008-06-17 | 2015-09-09 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴン／ｇｌｐ−１受容体コアゴニスト |
| JP5753779B2 (ja) * | 2008-06-17 | 2015-07-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体 |
| EP2987805A3 (en) | 2008-08-07 | 2016-04-13 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
| LT2349342T (lt) | 2008-10-17 | 2018-10-10 | Baxalta GmbH | Modifikuoti kraujo faktoriai, apimantys nedidelį vandenyje tirpaus polimero kiekį |
| DK2370461T3 (da) | 2008-12-15 | 2013-12-16 | Zealand Pharma As | Glucagonanaloger |
| BRPI0823377A2 (pt) | 2008-12-15 | 2016-09-27 | Zealand Pharma As | análogos de glucagon |
| MA32970B1 (fr) * | 2008-12-15 | 2012-01-02 | Zealand Pharma As | Analogues du glucagon |
| JP5635530B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| EP2398822B1 (en) | 2009-02-19 | 2013-01-02 | Novo Nordisk A/S | Modification of factor viii |
| BRPI1014508A2 (pt) | 2009-06-16 | 2016-04-05 | Univ Indiana Res & Tech Corp | análogos de peptídeo de glucagon, dimer de dois peptídeos de glucagon, composição farmacêutica deles derivada e métodos para seu uso" |
| JP6054742B2 (ja) | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
| GB0917072D0 (en) * | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| CN102933598A (zh) | 2010-03-26 | 2013-02-13 | 诺沃—诺迪斯克有限公司 | 新型胰高血糖素类似物 |
| AU2011231503C1 (en) | 2010-03-26 | 2016-03-03 | Novo Nordisk A/S | Novel glucagon analogues |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| US9169310B2 (en) * | 2010-06-24 | 2015-10-27 | Zealand Pharma A/S | Glucagon analogues |
| WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
| AR084558A1 (es) | 2010-12-22 | 2013-05-22 | Marcadia Biotech | Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1) |
| JP6086067B2 (ja) | 2010-12-22 | 2017-03-01 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | Ｇｉｐレセプター活性を示すグルカゴンアナローグ |
| PH12013501495A1 (en) | 2011-01-20 | 2013-09-16 | Zealand Pharma As | Combination of acylated glucagon analogues with insulin analogues |
| CN103596583B (zh) * | 2011-03-28 | 2016-07-27 | 诺沃—诺迪斯克有限公司 | 新型胰高血糖素类似物 |
| EP2694095B1 (en) | 2011-04-05 | 2018-03-07 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| EP2710031B9 (en) | 2011-05-18 | 2018-02-28 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for insulin resistance |
| JP6148228B2 (ja) | 2011-05-18 | 2017-06-14 | ユーメデリス ファーマシューティカルズ，インク． | 改善されたペプチド製剤 |
| ES2692187T3 (es) | 2011-06-10 | 2018-11-30 | Hanmi Science Co., Ltd. | Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de obesidad que lo comprende |
| MX347703B (es) | 2011-06-22 | 2017-05-09 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1. |
| US8729017B2 (en) | 2011-06-22 | 2014-05-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| CA2849673A1 (en) * | 2011-09-23 | 2013-03-28 | Novo Nordisk A/S | Novel glucagon analogues |
| PL2986313T3 (pl) | 2013-04-18 | 2019-12-31 | Novo Nordisk A/S | Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych |
-
2012
- 2012-09-21 CA CA2849673A patent/CA2849673A1/en not_active Withdrawn
- 2012-09-21 US US13/624,387 patent/US8541368B2/en active Active
- 2012-09-21 BR BR112014006684A patent/BR112014006684A2/pt not_active Application Discontinuation
- 2012-09-21 KR KR1020147010449A patent/KR20140070612A/ko not_active Withdrawn
- 2012-09-21 AU AU2012311484A patent/AU2012311484B2/en not_active Ceased
- 2012-09-21 IN IN2448CHN2014 patent/IN2014CN02448A/en unknown
- 2012-09-21 TW TW101134663A patent/TWI596110B/zh not_active IP Right Cessation
- 2012-09-21 JP JP2014531245A patent/JP6352806B2/ja not_active Expired - Fee Related
- 2012-09-21 RU RU2017101333A patent/RU2017101333A/ru unknown
- 2012-09-21 WO PCT/EP2012/068649 patent/WO2013041678A1/en not_active Ceased
- 2012-09-21 AR ARP120103494A patent/AR088161A1/es unknown
- 2012-09-21 MX MX2014003312A patent/MX354705B/es active IP Right Grant
- 2012-09-21 RU RU2014114434A patent/RU2610175C2/ru not_active IP Right Cessation
- 2012-09-21 MY MYPI2014000627A patent/MY167234A/en unknown
- 2012-09-21 EP EP12759773.0A patent/EP2758426B1/en active Active
- 2012-09-21 CN CN201280057736.1A patent/CN104093735B/zh not_active Expired - Fee Related
-
2013
- 2013-07-09 US US13/937,674 patent/US9486505B2/en active Active
-
2014
- 2014-02-27 IL IL231199A patent/IL231199A0/en unknown
- 2014-03-03 ZA ZA2014/01603A patent/ZA201401603B/en unknown
-
2015
- 2015-02-24 US US14/629,682 patent/US9486506B2/en active Active
-
2016
- 2016-08-16 US US15/237,958 patent/US20160347812A1/en not_active Abandoned
-
2017
- 2017-11-06 JP JP2017213869A patent/JP2018021081A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MY167234A (en) | 2018-08-14 |
| AR088161A1 (es) | 2014-05-14 |
| EP2758426A1 (en) | 2014-07-30 |
| US20130079278A1 (en) | 2013-03-28 |
| JP2018021081A (ja) | 2018-02-08 |
| CN104093735A (zh) | 2014-10-08 |
| ZA201401603B (en) | 2015-02-25 |
| US20130288958A1 (en) | 2013-10-31 |
| CN104093735B (zh) | 2018-07-06 |
| CA2849673A1 (en) | 2013-03-28 |
| IL231199A0 (en) | 2014-04-30 |
| US8541368B2 (en) | 2013-09-24 |
| US20160347812A1 (en) | 2016-12-01 |
| AU2012311484A1 (en) | 2014-03-06 |
| US20150182594A1 (en) | 2015-07-02 |
| JP2014527975A (ja) | 2014-10-23 |
| TWI596110B (zh) | 2017-08-21 |
| IN2014CN02448A (OSRAM) | 2015-06-19 |
| EP2758426B1 (en) | 2019-08-07 |
| TW201329102A (zh) | 2013-07-16 |
| US9486505B2 (en) | 2016-11-08 |
| WO2013041678A1 (en) | 2013-03-28 |
| BR112014006684A2 (pt) | 2017-03-28 |
| MX2014003312A (es) | 2014-04-25 |
| US9486506B2 (en) | 2016-11-08 |
| RU2610175C2 (ru) | 2017-02-08 |
| JP6352806B2 (ja) | 2018-07-04 |
| KR20140070612A (ko) | 2014-06-10 |
| AU2012311484B2 (en) | 2017-04-13 |
| RU2014114434A (ru) | 2015-10-27 |
| MX354705B (es) | 2018-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017101333A (ru) | Новые аналоги глюкагона | |
| JP2014527975A5 (OSRAM) | ||
| RU2012144289A (ru) | Новые аналоги глюкагона | |
| JP2013523619A5 (OSRAM) | ||
| RU2013145013A (ru) | Новые аналоги глюкагона | |
| JP2013523618A5 (OSRAM) | ||
| JP5669395B2 (ja) | 新規化合物および摂食行動に対するその効果 | |
| ES2976562T3 (es) | Derivado del glucagón | |
| US9861706B2 (en) | GLP-1 receptor agonist peptide gastrin conjugates | |
| JP2023071869A (ja) | グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト | |
| CN104144696A (zh) | 胰高血糖素类似物 | |
| EP2370462A1 (en) | Glucagon analogues | |
| RU2012128547A (ru) | Дважды ацилированные производные glp-1 | |
| KR20150116912A (ko) | 글루카곤 유사체 | |
| CN101203531A (zh) | 修饰的pyy（3-36）多肽及它们对进食行为的影响 | |
| CA2747112A1 (en) | Glucagon analogues | |
| MX2014013319A (es) | Análogos de péptido-2 tipo glucagón (glp-2). | |
| IL224951A (en) | Use of ave0010 to manufacture a drug to treat type 2 diabetes | |
| WO2013127196A1 (zh) | 环状核心序列与生物素或穿膜肽相连而成的促黑激素类似物 | |
| CA3222051A1 (en) | Polypeptide derivative having effect of dual targeted activation of glp-1r and gipr, preparation method therefor, and use thereof | |
| TW201105336A (en) | Combined medicine of pyrazole derivative and biguanide drug | |
| CA3073011C (en) | Acylated oxyntomodulin peptide analog | |
| CN115490760B (zh) | 一种glp-1受体和gcg受体共激动多肽衍生物 | |
| CN119431514A (zh) | 一种gcgr、gipr和glp-1r三重靶向激动作用的多肽衍生物 | |
| JP2024501467A (ja) | 新規化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA91 | Application withdrawn (on applicant's request) |
Effective date: 20190625 |